In 2025, kratom—a botanical derived from the leaves of the Southeast Asian Mitragyna speciosatree—has emerged from legal obscurity into the spotlight of state legislatures across the United States. As federal authorities continue to debate how best to address kratom’s safety and legal status, states are taking the lead, crafting new laws that legalize but regulate kratom to protect consumers, ensure product quality, and restrict access to minors.
The Patchwork of State Kratom Laws
Kratom’s legal status in the U.S. remains a patchwork of regulations. While it is not classified as a controlled substance at the federal level, individual states have taken widely divergent approaches. As of May 2025, at least 22 states have introduced legislation to either regulate or restrict kratom, with most opting for regulatory frameworks rather than outright prohibitions. This trend reflects a growing recognition of kratom’s popularity and the need for consumer protections in the absence of federal oversight.
The Rise of the Kratom Consumer Protection Act
A central feature of this regulatory movement is the adoption of the Kratom Consumer Protection Act, a model bill developed by the American Kratom Association (AKA) to establish standards for product safety, labeling, and age restrictions. The KCPA and similar bills have been enacted in at least 14 states, including Arizona, Georgia, Nevada, Utah, Oregon, Texas, Kentucky, and Maryland. These laws typically include:
-
Prohibiting sales to individuals under a specified age (usually 18 or 21)
-
Banning adulterated or contaminated products
-
Requiring clear labeling of active alkaloid content (mitragynine and 7-hydroxymitragynine)
-
Mandating child-resistant packaging and truthful marketing practices
-
Establishing penalties for non-compliance
The AKA supports such regulation, emphasizing the importance of protecting consumers from adulterated products and advocating for good manufacturing practices (GMP) among kratom vendors.
Age Restrictions and Labeling Requirements
A major focus of recent legislation is restricting kratom sales to adults. In New York, for example, Senate Bill S4552 and its Assembly counterpart prohibit the sale of kratom to individuals under 21 and require retailers to display signage about the age restriction, as well as to check identification at the point of sale. Similar age restrictions are being considered or have been enacted in Connecticut, Mississippi, Illinois, and several other states.
Labeling requirements are also becoming standard. New York’s Assembly Bill 5852 mandates that kratom products carry warning labels indicating the product has not been approved by the FDA and prohibits the use of terms like “all natural” on packaging. These measures aim to ensure consumers are fully informed about what they are purchasing.
Product Testing and Safety Standards
Some states are going further by requiring rigorous product testing and certification. Florida’s revised Kratom Consumer Protection Act (set to take effect January 1, 2025) mandates that all kratom products be tested by independent laboratories certified by the Department of Agriculture and Consumer Services (DACS). The law prohibits the sale of products adulterated with dangerous substances, contaminated with unsafe materials, or containing synthetic alkaloids. It also limits the amount of 7-hydroxymitragynine—a potent kratom alkaloid—to no more than two percent of the total alkaloid content in any product.
Retailers, wholesalers, and manufacturers must all ensure their products meet these standards, and the law provides for penalties, including the seizure and destruction of non-compliant products. The Florida law also restricts kratom sales near schools and authorizes certain alcohol licensees to sell kratom, integrating the product into existing regulatory frameworks for other adult products.
Local Control and Potency Limits
Some states, such as Mississippi, are balancing statewide regulation with local control. House Bill 1077 sets a minimum purchase age of 21 and bans synthetic kratom, while allowing counties and cities to enact their own bans if they choose. The bill also imposes strict potency limits, capping 7-hydroxymitragynine content at one percent of the alkaloid fraction and no more than 0.5 milligrams per container.
Industry and Advocacy Perspectives
The kratom industry and advocacy groups like the American Kratom Association have played a significant role in shaping state legislation. The AKA’s GMP standards program, for example, certifies manufacturers who adhere to strict safety and quality requirements, including independent audits, proper recordkeeping, and adverse event reporting. The organization supports age restrictions, labeling, and child-resistant packaging, and has actively lobbied for regulatory rather than prohibitive approaches.
According to the AKA, kratom’s pattern of use and potential for abuse is similar to that of unscheduled substances like caffeine, and the organization argues that there have been no fatal overdoses associated with pure kratom. The group’s advocacy has helped steer legislative efforts toward consumer protection and away from outright bans.
States Moving from Prohibition to Regulation
Interestingly, some states that previously prohibited kratom are now considering regulatory frameworks. Rhode Island, for example, has a bill pending in 2025 that would repeal the state’s scheduling of kratom as a controlled substance and replace it with a regulatory scheme ensuring safe, properly labeled, and age-restricted products. Similar reversals are under discussion in Indiana, Wisconsin, and Vermont, reflecting a broader shift toward regulation as the preferred policy approach.
The Federal Regulatory Void
The absence of federal regulation remains a key driver of state action. While the Drug Enforcement Administration has designated kratom as a “drug and chemical of concern,” it has not scheduled kratom as a controlled substance, and congressional efforts to study kratom have stalled. This regulatory gap has left states to develop their own rules, resulting in a diverse legal landscape.
Montana’s ongoing legislative debate exemplifies the challenges of state-level regulation. Lawmakers there are considering a bill based on the KCPA, which would ban sales to minors and set standards for product labeling and potency. However, questions remain about the state’s capacity to enforce these rules and the effectiveness of industry self-regulation.
The Future of Kratom Regulation
As of spring 2025, 24 states and the District of Columbia have enacted some form of kratom regulation, with more states expected to follow suit. The trend is clear: rather than prohibiting kratom, legislatures are choosing to legalize it under strict regulatory frameworks designed to protect consumers, ensure product quality, and restrict access to minors.
This new era of kratom regulation reflects a pragmatic approach that balances the interests of public health, consumer choice, and industry growth. As research into kratom’s effects continues and federal policy evolves, state-level regulation is likely to remain the primary mechanism for ensuring the safety and integrity of kratom products in the United States.